These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33455598)

  • 1. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.
    Pfaus JG; Sadiq A; Spana C; Clayton AH
    CNS Spectr; 2022 Jun; 27(3):281-289. PubMed ID: 33455598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options.
    Croft HA
    J Sex Med; 2017 Dec; 14(12):1575-1584. PubMed ID: 29198512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
    Mayer D; Lynch SE
    Ann Pharmacother; 2020 Jul; 54(7):684-690. PubMed ID: 31893927
    [No Abstract]   [Full Text] [Related]  

  • 4. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
    Simon JA; Kingsberg SA; Portman D; Jordan R; Lucas J; Sadiq A; Krop J; Clayton AH
    J Womens Health (Larchmt); 2022 Mar; 31(3):391-400. PubMed ID: 35230162
    [No Abstract]   [Full Text] [Related]  

  • 5. The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.
    Kingsberg SA; Clayton AH; Pfaus JG
    CNS Drugs; 2015 Nov; 29(11):915-33. PubMed ID: 26519340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
    Althof S; Derogatis LR; Greenberg S; Clayton AH; Jordan R; Lucas J; Spana C
    J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
    Koochaki P; Revicki D; Wilson H; Pokrzywinski R; Jordan R; Lucas J; Williams LA; Sadiq A; Krop J
    J Womens Health (Larchmt); 2021 Apr; 30(4):587-595. PubMed ID: 33538638
    [No Abstract]   [Full Text] [Related]  

  • 8. Bremelanotide: First Approval.
    Dhillon S; Keam SJ
    Drugs; 2019 Sep; 79(14):1599-1606. PubMed ID: 31429064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and Management of Hypoactive Sexual Desire Disorder.
    Clayton AH; Kingsberg SA; Goldstein I
    Sex Med; 2018 Jun; 6(2):59-74. PubMed ID: 29523488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women.
    Barakeh D; Mdaihly H; Karaoui LR
    Ann Pharmacother; 2024 May; ():10600280241253273. PubMed ID: 38767282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.
    Cipriani S; Alfaroli C; Maseroli E; Vignozzi L
    Expert Opin Pharmacother; 2023 Jan; 24(1):15-21. PubMed ID: 36242769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flibanserin for female sexual dysfunction.
    Reviriego C
    Drugs Today (Barc); 2014 Aug; 50(8):549-56. PubMed ID: 25187905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
    Diamond LE; Earle DC; Heiman JR; Rosen RC; Perelman MA; Harning R
    J Sex Med; 2006 Jul; 3(4):628-638. PubMed ID: 16839319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study.
    Allers KA; Dremencov E; Ceci A; Flik G; Ferger B; Cremers TI; Ittrich C; Sommer B
    J Sex Med; 2010 May; 7(5):1757-67. PubMed ID: 20163532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
    Kingsberg SA; Clayton AH; Portman D; Williams LA; Krop J; Jordan R; Lucas J; Simon JA
    Obstet Gynecol; 2019 Nov; 134(5):899-908. PubMed ID: 31599840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder.
    Stahl SM; Sommer B; Allers KA
    J Sex Med; 2011 Jan; 8(1):15-27. PubMed ID: 20840530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bremelanotide for Treatment of Female Hypoactive Sexual Desire.
    Edinoff AN; Sanders NM; Lewis KB; Apgar TL; Cornett EM; Kaye AM; Kaye AD
    Neurol Int; 2022 Jan; 14(1):75-88. PubMed ID: 35076581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
    Dhanuka I; Simon JA
    Expert Opin Pharmacother; 2015; 16(16):2523-9. PubMed ID: 26395164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment.
    Kingsberg SA; Simon JA
    J Womens Health (Larchmt); 2020 Aug; 29(8):1101-1112. PubMed ID: 32460605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight Loss in Women Taking Flibanserin for Hypoactive Sexual Desire Disorder (HSDD): Insights Into Potential Mechanisms.
    Simon JA; Kingsberg SA; Goldstein I; Kim NN; Hakim B; Millheiser L
    Sex Med Rev; 2019 Oct; 7(4):575-586. PubMed ID: 31196764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.